How duty cuts in cancer drugs will ease burden for patients

Duty Cuts in Cancer Drugs: Balancing Accessibility with Affordability

The tension between affordability in curative healthcare and systemic challenges in equitable access defines the policy shift on duty cuts for cancer drugs. India, with its high incidence of cancer cases and fragmented healthcare financing, faces mounting pressure to bridge the gap between treatment costs and patient capacity to pay. This article examines the implications of duty reductions, anchoring the debate within global frameworks like healthcare equity and SDG 3 (Ensure Healthy Lives and Promote Well-being). It critically evaluates policy design, implementation capacity, and the structural issues involved.

UPSC Relevance Snapshot

• GS-II (Health Governance): Policies to enhance access to healthcare; international frameworks on equitable health delivery.
• GS-II (Government Policies): Import duty rationalization and its impact on financial inclusion in healthcare.
• GS-III (Economic Development): Health financing and cost rationalization as part of public expenditure priorities.
• Essay Context: Bridging affordability and access in a growing healthcare burden — ethical and fiscal dimensions.

Arguments in Favor of Duty Cuts

Duty reductions on cancer drugs address the affordability barrier in curative healthcare, aligning with both national health obligations and the ethical imperatives of equitable healthcare delivery. Cancer treatment in India is exceedingly expensive, with out-of-pocket health expenditures accounting for nearly 60% of health spending (World Bank WDI). Removing high import duties can significantly reduce consumer costs, granting relief to economically vulnerable sections of society.

• Poverty-alleviation through healthcare savings: WHO studies highlight that catastrophic health expenditure due to non-communicable diseases like cancer pulls households below the poverty line. Duty cuts mitigate this effect.
• NFHS-5 inclusion data: NFHS-5 shows less than 2% insurance coverage for outpatient treatments, highlighting the unaffordable cost of drugs. Duty rationalization can improve access within this underserved group.
• Equity-driven targeting: Reducing duties aligns with SDG 3.8 on achieving universal health coverage, especially for vulnerable populations. Imported cancer drugs—used for complex therapies like immunotherapy—become more affordable across socio-economic strata.
• Economic incentives for pharmaceutical growth: Lower duties can incentivize imports of advanced cancer medications, fostering a competitive domestic manufacturing ecosystem over time.

Arguments Against Duty Cuts

Despite its apparent benefits, duty rationalization faces critiques regarding long-term sustainability and fund reallocation dilemmas within government health programs. Critics argue for structural health investments instead, such as broader health insurance spread and improved public cancer treatment facilities, as a holistic solution instead of piecemeal fiscal reforms.

• Revenue loss impact: Analysis from Economic Survey 2025 reveals import duty reductions on critical drugs could cause significant revenue losses (~₹700 crore annually), affecting public health infrastructure spending.
• Selective affordability mismatch: Imported cancer drugs target elite treatment cases; their affordability may increase but remains inaccessible for a majority reliant on public hospitals.
• Systemic dependency risks: Over-reliance on imports discourages domestic innovation in oncology drugs, perpetuating dependency on foreign pharmaceutical firms.
• Regulatory bottlenecks: Price rationalization may not guarantee patient access due to parallel challenges of distribution inefficiencies and middlemen profit margins (CAG Report 2023).

Comparative Policy Approach: India vs France

What the Latest Evidence Shows

Recent RTI disclosures (October 2023) highlight that after duty cuts on select oncology drugs, patient costs dropped by an average of 30% for eligible therapies (NITI Aayog estimates). However, NFHS-5 reports continue to reveal low penetration of treatment accessibility in tier-2 and tier-3 cities. Additionally, WHO’s 90-70-90 target underscores gaps in early diagnosis rates compared to improved therapeutic financing, reflecting an imbalanced treatment ecosystem.

Global cancer control initiatives such as the Union for International Cancer Control stress integrated models combining drug affordability with preventive interventions. India's duty reduction policy, though timely, lacks complementary mechanisms to address broader oncology service disparities.

Structured Assessment

• Policy Design: The initiative marks a financially-focused approach but neglects system-wide health equity considerations.
• Governance Capacity: Weak regulatory monitoring on end-user pricing and logistical bottlenecks for drug delivery impede equitable distribution.
• Behavioural/Structural Factors: India’s fragmented insurance architecture and urban-centric treatment model exacerbate availability gaps for rural and lower-income populations.

For instance, the challenges of equitable healthcare delivery are similar to those seen in other policy areas, such as the implementation of rural job acts, where systemic bottlenecks hinder progress. Similarly, the waning cooling effect in other sectors reflects the need for comprehensive structural reforms.

Exam Integration